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ORIGINAL RESEARCH
Objective: The aim of the present investigation was to evaluate the influence of serum
triglycerides (TG) on other plasma lipids in patients to be treated for dyslipidemia.
Methodology: Lipid profiles of a cohort of 801 patients (487 males and 314 females) aged
57 ± 9 years (mean ± SD) were evaluated. Patients were stratified according to their plasma
lipid levels. They were divided into various groups on the basis of serum TG (≥ 150 or
< 150 mg/dL) and high-density lipoprotein cholesterol (HDL-C) (≥ 40 or < 40 mg/dL).
Results: Patients with TG ≥ 150 mg/dL had a higher total cholesterol and lower HDL-C levels
compared with those with TG < 150 mg/dL, (p < 0.001). Patients with HDL-C < 40 mg/dL had
a lower serum total cholesterol and higher TG compared with those with HDL-C ≥ 40 mg/dL
(p = 0.011 and p < 0.0001, respectively). In all patients as well as in the subgroups, an inverse
correlation between TG and HDL-C was found (r = –0.377, p < 0.001).
Conclusions: Although, the metabolic pathway for TG and HDL-C is closely linked, an
inverse correlation between TG and HDL-C levels seems to exist in the entire sampled
population. This correlation also appears to persist in fasting patients with low levels of TG.
Keywords: triglycerides, high-density lipoprotein cholesterol, dyslipidemia
Introduction
Increased levels of low-density lipoprotein cholesterol (LDL-C) are a well established
risk factor for coronary artery disease (CAD) (Stamler et al 1986; The Scandinavian
Simvastatin Survival Study Group 1994). The Prospective Cardiovascular Münster
Study first unambiguously demonstrated that increased triglyceride (TG)
concentration is an independent risk factor for major coronary artery events, even
after adjustment for other positive CAD risk factors such as LDL-C and negative risk
factors such as high-density lipoprotein cholesterol (HDL-C) levels (Assmann et al
1996). Although, it has taken many years to establish HDL-C as a risk factor for
premature cardiovascular disease, it is now considered as an additional recognized
target for the prevention and treatment of atherosclerosis (Kolovou and Cokkinos
2002). Certainly, Foody and colleagues (2000) have reported that HDL-C was the
single most important predictor of survival after coronary artery bypass grafting in
men.
Epidemiological evidence, based on data from Western countries, seems to support
the concept of an inverse relationship between plasma TG levels to HDL-C cholesterol
levels (Anonymous 1993). In a pathologic state such as the metabolic syndrome, the
tandem high TG–low HDL-C occurs in a higher frequency, which cannot readily be
considered as coincidental. Moreover, the report from the Expert Group on HDL-C
points to the fact that many individuals with low plasma levels of HDL-C also have
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high levels of TG (Sacks 2002). Taken together, this may
imply the existence of a specific metabolic relationship
between the two molecules (ie, TG and HDL-C). In the
present investigation, our aim was to evaluate the
relationship between serum TG and HDL-C levels in patients
with lipidemic disorders intended to be treated with lipid-
lowering agents.
Materials and methods
Study design and population
Subjects for this investigation were selected from patients
who were not being treated with lipid-lowering agents prior
to referral to our Lipid Clinic. All patients were advised of
lifestyle changes to be followed for at least 3 months. After
this interval, fasting plasma samples for routine lipid analysis
were obtained in a cohort of 801 patients aged 57 ± 9 years
(mean ± SD). The gender composition of the group under
the investigation was 487 (61%) males and 314 (39%)
females. None of the females in this investigation were on
hormone replacement therapy. All subjects fulfilled one or
more of the following criteria: (1) total cholesterol (TC)
> 240 mg/dL, or > 170 mg/dL in patients with CAD; (2) TG
values > 150 mg/dL; and/or (3) HDL-C < 40 mg/dL.
In addition, based on TG and HDL-C levels, patients
were subdivided into the following groups: (a) TG levels
< 150 mg/dL or ≥ 150 mg/dL; (b) HDL-C levels, < 40 mg/dL
or ≥ 40 mg/dL; (c) TG ≥ 150 mg/dL and HDL-C ≥ 40 mg/dL;
(d) TG ≥ 150 mg/dL and HDL-C < 40 mg/dL; (e) TG
< 150 mg/dL and HDL-C ≥ 40 mg/dL; and (f) TG < 150 mg/dL
and HDL-C < 40 mg/dL.
Blood chemistry
The plasma levels of TC, TG, and HDL-C were measured
using enzymatic colorimetric methods on Roche Integra
Biochemical analyzer with commercially available kits
(Roche Diagnostics GmbH, Mannheim, Germany). The
serum LDL-C levels were calculated in patients with fasting
TG concentrations < 4.5 mmol/l (400 mg/dL) using the
Friedewald formula (Friedewald et al 1972).
Statistical analysis
Categorical variables are presented as percentages and
numerical characteristics as mean values with one SD. Chi-
square test was used for the comparison of categorical
variables and t-test for independent samples or Mann
Whitney U test for the comparison of numerical values
following testing for normality. Correlation between HDL-C
and TG was performed using Spearman correlation
coefficient. A p-value of < 0.05 was taken to be significant.
Results
Characteristics of patients
Concentration of lipids in men, women, and the combined
cohort are shown in Table 1. A small percentage of the
population under investigation had only one abnormal lipid
parameter; ie, 24.5% had increased TC levels (≥ 240 mg/dL),
2.7% had increased TG levels (≥ 150 mg/dL), while 4.2%
of the cohort had low HDL-C levels (< 40 mg/dL).
Additionally, the percentages of the patients’
anthropometric characteristics were estimated in a sample
of 286 subjects, of which 47% were smokers, 19% had
arterial hypertension, 7% had diabetes mellitus, 40% had
CAD, and 20% had experienced one myocardial infarction.
Composition of cohort based on TG
levels (≥ ≥ ≥ ≥ ≥ 150 or < 150 mg/dL)
Of the 801 subjects, 6.7% had normal TC levels with TG
levels ≥ 150mg/dL–HDL-C < 40 mg/dL, while 22.7%, 8.4%,
and 23.3% had abnormal TC levels with: TG ≥ 150 mg/dL–
HDL-C ≥ 40 mg/dL, TG < 150 mg/dL–HDL-C < 40 mg/dL,
and TG ≥ 150 mg/dL–HDL-C < 40 mg/dL, respectively.
Table 1 Concentration of various lipids in men, women, and the combined cohort
All patients Men Women
Mean SD Mean SD Mean SD pa
N 801 487 314
Age (years) 57 9 56 9 59 8 < 0.001
TC (mg/dL) 288 64 286 63 291 64 0.136
LDL-C (mg/dL) 207 62 207 61 207 64 0.994
TG (mg/dL) 182 101 187 100 174 102 0.009
HDL-C (mg/dL)  44 15 41 13 49 15 < 0.001
TC/HDL-C 7.1 2.7 7.4 2.7 6.5 2.6 < 0.001
a p-values refer to correlations between men and women.
Abbreviations for Tables 1–5: N, number of patients; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol;
TG, triglycerides. NOTE: To convert TC, HDL-C, and LDL-C from mg/dL to mmol/L divide by 38.7. To convert TG from mg/dL to mmol/L divide by 88.6.Vascular Health and Risk Management 2005:1(2) 157
Triglyceride and HDL-C levels
Patients with serum TG levels ≥ 150 mg/dL had lower
HDL-C levels (p < 0.001), higher TC levels (p < 0.001), and
higher TC/HDL-C ratio (p < 0.001) compared with those
with serum TG levels < 150 mg/dL. However, the two groups
had similar LDL-C levels (Table 2).
Composition of cohort based on HDL-
C levels (≥ 40 or < < < < < 40 mg/dL)
Patients with HDL-C < 40 mg/dL had a significantly lower
TC and higher TG levels compared with those with HDL-C
≥ 40 mg/dL and similar LDL-C levels. The patients with
higher HDL-C levels demonstrated significantly lower
TC/HDL-C ratio (Table 3).
Composition of cohort based on HDL-C
(≥ ≥ ≥ ≥ ≥ 40 or < < < < < 40 mg/dL) and TG (≥ 150 or
< < < < < 150 mg/dL) levels
To examine the distribution of patients with two or more
risk factors and to compare their lipid profile, we divided
the population according to their HDL-C and TG levels.
Patients with TG levels < 150 mg/dL and HDL-C levels
≥ 40 mg/dL were the largest group (32% of the study
population), and those with TG levels < 150 mg/dL and
HDL-C levels < 40 mg/dL were the smallest group (13% of
the study population). The group with TG levels ≥ 150 mg/dL
and HDL-C levels ≥ 40 mg/dL and the group with TG levels
≥ 150 mg/dL and HDL-C < 40 mg/dL were 25% and 30%
of all study patients, respectively (Table 4).
Patients with TG levels ≥ 150 mg/dL and HDL ≥ 40 mg/dL
had higher TC, lower TG levels, and lower TC/HDL-C ratio
compared with those with TG levels ≥ 150 mg/dL and HDL-C
levels < 40 mg/dL. Similar results were found in patients
with TG levels < 150 mg/dL. Those with HDL-C levels
≥ 40 mg/dL demonstrated higher TC and lower TG and
TC/HDL-C ratio. In patients with TG ≥ 150 mg/dL and
HDL-C ≥ 40 mg/dL, the highest TC levels were observed.
Patients with TG ≥ 150 mg/dL and HDL < 40 mg/dL had the
highest TG levels, the highest TC/HDL-C ratio, and the
lowest HDL-C levels. Patients with TG < 150 mg/dL and
HDL ≥ 40 mg/dL had the highest HDL-C levels and the
lowest TG levels and TC/HDL-C ratio (Table 4).
Composition of cohort based on gender
and TG levels (≥ 150 or < < < < < 150 mg/dL)
Women were found to have higher HDL and lower TG levels
as well as a lower TC/HDL-C ratio than men (Table 1). When
both genders were selected according to TG levels, they
followed the same lipid profile pattern (Table 5).
Table 2 Concentration of various lipids in subgroups with
triglycerides ≥ 150 or < < < < < 150 mg/dL
TG ≥ ≥ ≥ ≥ ≥ 150 mg/dL TG < < < < < 150 mg/dL
Mean SD Mean SD p
N 444 357
Age (years) 57 9 57 9 0.210
TC (mg/dL) 296 64 278 61 < 0.001
LDL-C (mg/dL) 207 65 208 59 0.517
TG (mg/dL) 242 98 105 27 < 0.001
HDL-C (mg/dL)  41 14 49 14 < 0.001
TC/HDL-C 7.8 2.7 6.1 2.4 < 0.001
Table 3 Concentration of various lipids in subgroups with
HDL-C ≥ ≥ ≥ ≥ ≥ 40 or < < < < < 40 mg/dL
HDL-C HDL-C
≥ ≥ ≥ ≥ ≥ 40 mg/dL  < < < < < 40 mg/dL
Mean SD Mean SD p
N 460 341
Age (years) 57 9 56 9 0.167
TC (mg/dL) 292 61 282 67 0.011
LDL-C (mg/dL) 207 60 206 65 0.641
TG (mg/dL) 156 83 216 112 < 0.0001
HDL-C (mg/dL) 53 13 32 5 < 0.0001
TC/HDL-C 5.7 1.5 9.0 2.7 < 0.0001
Table 4 Concentration of various lipids in subgroups with triglycerides ≥ 150 or < < < < < 150 mg/dL and HDL-C ≥ 40 or < < < < < 40 mg/dL
TG ≥ ≥ ≥ ≥ ≥ 150 mg/dL TG ≥ ≥ ≥ ≥ ≥ 150 mg/dL TG < < < < < 150 mg/dL TG < < < < < 150 mg/dL
and HDL-C and HDL-C and HDL-C and HDL-C
≥ ≥ ≥ ≥ ≥ 40 mg/dL < < < < < 40 mg/dL ≥ ≥ ≥ ≥ ≥ 40 mg/dL < < < < < 40 mg/dL
Mean SD Mean SD p Mean SD Mean SD p
N 204 240 256 101
Age (years) 57 8 56 9 0.141 57 9 57 9 0.907
TC (mg/dL) 303 59 290 68 0.007 284 61 263 59 0.01
LDL-C (mg/dL) 207 61 206 68 0.486 208 60 208 58 0.764
TG (mg/dL) 224 80 259 105 < 0.0001 103 28 111 23 0.018
HDL-C (mg/dL) 51 14 32 5 < 0.0001 55 12 33 5 < 0.0001
TC/HDL-C 6.2 1.5 9.2 2.6 < 0.0001 5.3 1.4 8.3 2.9 < 0.0001Vascular Health and Risk Management 2005:1(2) 158
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Correlations
A correlation between HDL-C and TG was found to exist
in the entire population that was studied (r = –0.377,
p < 0.001) (Figure 1). HDL-C levels were correlated to the
TG concentration in patients with HDL-C < 40 mg/dL
(r = –0.139, p < 0.010) and with HDL-C ≥ 40 mg/dL
(r = –0.284, p < 0.001). Additionally, HDL-C levels were
correlated to the TG concentration in patients with TG
≥ 150 mg/dL (r = –0.224, p < 0.0001), and with TG < 150 mg/dL
(r = –0.223, p < 0.0001) (Figure 2). After segregating the
population according to HDL-C cut-off point of 40 or TG
cut-off point of 150, an inverse correlation was found ([r =
 –0.139, p = 0.01] and [r = –0,284, p < 0.0001], respectively).
When examined the correlations between TG and HDL-C
in terms of quartile of TG, significant inverse correlations
were observed in the 3rd quartile in women (r = –0.275,
p = 0.015) and in the 1st, 2nd, and 3rd quartiles in the
combined cohort ([r = –0.222, p = 0.002] [r = –0.214,
p = 0.003] and [r = –0.147, p = 0.036], respectively). There
was no significant correlation found in any quartile in men.
Discussion
The data in the present study support the view that in
untreated dyslipidemic patients, the fasting TG levels
correlated inversely with HDL-C levels. This correlation not
only exists in the condition where TG levels are high but
also when TG levels are low.
Over 25 years ago, data from the Framingham Heart
Study demonstrated that TG levels can influence the CAD
risk only in patients with low HDL-C concentration (Castelli
1986). Now, after numerous reports, the association of high
TG concentration with low HDL-C levels is well established
among patients with CAD (Jeppesen et al 2003), diabetes
mellitus (Wilson et al 1985; Teno et al 2000), metabolic
syndrome (Reaven 1988; Jeppesen et al 1997), familial
combined dyslipidemia (Soro et al 2003), and Tangier
disease (Kolovou et al 2003). Our current study confirmed
that patients with HDL-C < 40 mg/dL, which is considered
as low levels according to the last ATP III (Expert Panel on
Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults 2001), have higher serum TG levels
Table 5 Concentration of various lipids in subgroups with triglycerides ≥ 150 or < 150 mg/dL in men and women
Men with TG Men with TG Women with TG Women with TG
≥ ≥ ≥ ≥ ≥ 150 mg/dL < < < < < 150 mg/dL ≥ ≥ ≥ ≥ ≥ 150 mg/dL < < < < < 150 mg/dL
Mean SD Mean SD p Mean SD Mean SD p
N 286 199 155 155
Age (years) 56 9 56 10 0.442 59 8 59 8 0.827
TC (mg/dL) 293 60 275 66 0.001 301 71 281 55 0.018
LDL-C (mg/dL) 205 61 209 62 0.697 209 72 206 55 0.555
TG (mg/dL) 242 95 108 27 < 0.0001 246 99 102 27 < 0.0001
HDL-C (mg/dL)  39 14 45 12 < 0.0001 43 13 54 16 < 0.0001
TC/HDL-C 8.0 2.6 6.5 2.4 < 0.0001 7.4 2.6 5.6 2.3 < 0.0001
TG (mg/dL)
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Figure 1 The correlation of high-density lipoprotein cholesterol (HDL-C) with
triglyceride (TG) levels in the entire population.
Figure 2 The correlation between high-density lipoprotein cholesterol (HDL-C)
with triglyceride (TG) levels in patients with TG levels < 150 mg/dL.
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(p < 0.0001) compared with patients with HDL-C levels
≥ 40 mg/dL. This relationship between low HDL and high
TG levels appears to be independent of other plasma lipids.
In addition, in these patients an inverse correlation between
TG and HDL-C levels was found. Moreover, such
correlation was found in the entire population presently
studied (even in those with low TG levels) independently
of HDL-C. The suggestion that the correlation between TG
and HDL-C levels in the group with HDL-C level
< 40 mg/dL was strong enough to influence the correlation
in the whole study population is plausible. However, we
have also found the same correlation among patients with
normal or low TG levels and among patients with normal
or high HDL-C levels. Up to now, it was not clearly
established if the serum levels of TG correlated in any
fashion with the HDL-C levels. Evidence published in the
current literature seems to indicate that the correlation
between TG and HDL-C levels is not a simple one. For
example, Le and Ginsberg (1988) have demonstrated
heterogeneity in apolipoprotein A-I turnover in patients with
different TG and HDL-C levels. While it has been suggested
that TGs could influence HDL and apolipoprotein A-I
turnover and clearance (Lamarche et al 1999). Our present
results show that even in patients with HDL-C ≥ 40 mg/dL,
TG concentration inversely correlates with the HDL-C
levels.
Evidence from the Québec Cardiovascular Study
demonstrated a correlation between fasting TG and HDL-
C levels (Lamarche et al 1996). In the latter study, whilst a
significant inverse relationship (r = –0.49, p < 0.0001)
between TG and HDL-C levels was reported, the correlation
was not linear as most of the variance in HDL-C levels was
found within TG concentration below 2.5 mmol/L
(221.5 mg/dL) (Lamarche et al 1996). In addition, in patients
with TG levels above 3.0 mmol/L (265.8 mg/dL), a further
increase of TG did not provoke additional reduction in HDL-
C levels. The difference between our present findings and
the Québec Cardiovascular Study (Lamarche et al 1996)
may be attributed to the fact that some of the patients in the
latter study were being treated with lipid-lowering agents.
Moreover, the entire cohort of the patient pool consisted of
men, and grouping was made according to the cut-off point
as set by the Canadian Consensus Conference on Cholesterol
(1988).
A number of epidemiological studies have demonstrated
a negative correlation between HDL-C levels and CAD. It
seems that no relationship between fasting TG concentration
and atherosclerosis could be found if the TG concentrations
were examined alone without HDL-C. Thus, it has been
suggested that the negative correlation between serum TG
and HDL-C concentrations is a good marker, which may be
used to tie the state of hypertriglyceridemia with CAD
(Hulley et al 1980; Austin 1991; Lamarche et al 1996).
One hypothesis, which has been proposed by Patsch and
colleagues (1987; Gotto et al 1991) to explain the correlation
between HDL-C and TG levels, suggests that a low
concentration of HDL-C is the consequence of non efficient
postprandial clearance of TG-rich lipoproteins and that it is
a marker of postprandial hypertriglyceridemia. This latter
phenomenon can, at least, in part, explain the correlation
between low TG and high HDL-C levels found in our study.
However, it is likely that the relation between HDL-C–TG
is bidirectional and that it encompasses more than one
metabolic route. For example, in a hypertriglyceridemic
state, the coupling low HDL-C–high TG may be related to
one of the following states:
1. The HDL particles are TG-enriched via cholesteryl ester
transfer protein mediated exchange with TG-rich
lipoproteins. The HDL-TG enriched particles are cleared
more rapidly from the circulation (Lamarche et al 1999),
leading to low HDL-C levels.
2. The TG-enriched HDL particles are a better substrate for
intravascular lipolysis, resulting in smaller HDL particle
size, which leads to faster HDL clearance (Brunzell et
al 1983; Santamarina-Fojo et al 1994).
3. The decreased lipoprotein lipase activity reduces the
availability of surface constituents of TG-rich
lipoproteins, which are important to the nascent HDL
particle forming (Eisenberg 1984; Brewer et al 1991).
It seems that the content of serum in terms of lipids in the
fasting state is a consequence of the postprandial state. There
are some exceptions with positive correlation between TG
and HDL-C levels such as in high alcohol intake (Rimm et
al 1999) and estrogen replacement therapy (Mercuro et al
2003). Reportedly, males, generally, present worse lipid and
lipoprotein profiles when compared with women (Godsland
et al 1987). Similarly, in our study, men had higher TG and
TC/HDL-C ratio and lower HDL-C levels than the women.
However, when their lipid profile was examined according
to TG levels (≥ 150 or < 150 mg/dL), men and women
followed the same pattern when compared with the
combined cohort. Nevertheless, the profile for males is
characterized by an increased abdominal fat accumulation
compared with women, despite having similar levels of totalVascular Health and Risk Management 2005:1(2) 160
Kolovou et al
body fat (in kilograms) (Couillard et al 1999). Also in men,
the plasma TG levels peak later during the postprandial
period suggesting impaired postprandial clearance.
However, no differences have been found between men and
women when visceral adipose tissue accumulation was
assessed (Couillard et al 1999).
A number of genes are responsible for the synthesis,
transport, and clearance of TG and HDL. The apolipoprotein
CIII polymorphism (Ordovas et al 1991) and the lipoprotein
lipase deficiency (Anonymous 1993) seem to lead to
hypertriglyceridemia, but not to obligatory low HDL-C
levels. However, apolipoprotein CIII gene is considered as
the main candidate for the TG levels control, since
apolipoprotein CIII inhibits the lipoprotein lipase. The
apolipoprotein CIII gene is a member of a gene cluster on
chromosome 11, including apolipoprotein AI and
apolipoprotein AIV genes, which are related to the HDL
synthesis and removal. Mutations in the ATP-binding
cassette transporter A1 mutations result in the formation of
a defective HDL (Clee et al 2000), frequently accompanied
with high plasma TG levels. According to the
contemporaneous knowledge, it is difficult to explain the
correlations between TG and HDL-C levels with metabolic
pathways, which are under a single-gene control.
In comparing our present data to other studies, some
observations on the frequency of variable HDL-C levels in
patients free of medication can be made. In the present
population, the frequency of low HDL-C levels was 42.5%,
while in the Israeli Ischemic Heart Disease Study it was
31% in male subjects without CAD and a HDL-C level of
< 35 mg/dL (Goldbourt et al 1997). In contrast, the
prevalence of low HDL-C in USA is only 15% among the
general male population and 5% among the general female
population (Maron 2000). The discrepancy between our
study and the US study is probably due to the fact that the
population we studied was dyslipidemic and did not
represent the general Greek population. As well, the high
use of hormone replacement therapy in the US may have an
impact on the observed differences in the prevalence of low
HDL. On the other hand, the Mediterranean diet of the Greek
population differs in terms of a lower intake of saturated
fatty acids when compared with the dietary habits in the US
population; a fact that should benefit the lipid profile of the
Greek population, but one that cannot be concluded based
on the present data. The higher prevalence of low HDL
observed in our patient population could also be attributed
to differences in genetic background and to factors such as
the higher tobacco smoking and lower alcohol consumption
of the Greek population in contrast to other populations
(Fumeron et al 1995; Kauma et al 1996). Our data are
probably closer to those from the Québec Cardiovascular
Study (Lamarche et al 1996). In the patient group without
CAD, low HDL-C levels were observed in 30% (vs 42.5%
in our study) and high TG levels in 20% (vs 75.3% in our
study).
Certainly, information on height and weight of the
patients could be valuable in estimating the prevalence of
the metabolic syndrome in the present population.
Unfortunately, such data were not systematically collected
and this lack of information could be considered a limitation
of the present study.
In conclusion, an inverse correlation between fasting TG
and HDL-C levels was found among dyslipidemic untreated
patients. The most interesting finding is that this correlation
seems to exist also in subjects with low TG levels. The
relationship between TG-HDL-C remains stable in all
patients’ phenotypes and indirectly implies that TG and
HDL-C levels depend on common metabolic pathway(s).
This correlation should be taken into consideration when
the risk of atherosclerosis is evaluated.
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